Lycopene CAS: 502-65-8

CAS NO: 502-65-8
Lycopene
Chemical Name: Lycopene
Molecular Formula: C40H56
Formula Weight: 536.87
CAS No.: 502-65-8
Description Review
Description

Lycopene is a natural carotenoid compound found in tomatoes, watermelon, papaya, and other fruits and vegetables. Its chemical name is 2,6,10,14-tetramethylpentadeca-2,5,8,11,14-ene- caroten-3-one, and its molecular formula is C40H56, with a molecular weight of 536.88 g/mol. The CAS number for lycopene is 502-65-8.

Top Ten Keywords and Synonyms:

  1. Lycopene supplement
  2. Tomato extract
  3. Antioxidant properties
  4. Anti-inflammatory effects
  5. Cardiovascular benefits
  6. Cancer prevention
  7. Prostate health
  8. Carotenoid
  9. Red pigment
  10. Skin health

Health Benefits of Lycopene: Lycopene has been studied extensively for its potential health benefits. It possesses antioxidant, anti-inflammatory, cardiovascular, and anticancer properties.

  1. Antioxidant Properties: Lycopene has potent antioxidant properties which help to scavenge free radicals and reduce oxidative stress in cells. These properties make it a potential therapeutic agent for various chronic diseases such as cancer, neurodegenerative disorders, and cardiovascular diseases.

  2. Anti-inflammatory Effects: Lycopene exerts an anti-inflammatory effect by inhibiting the expression of pro-inflammatory cytokines and enzymes such as interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2 (COX-2). This makes it a potential treatment for inflammatory diseases such as rheumatoid arthritis and asthma.

  3. Cardiovascular Benefits: Lycopene has beneficial effects on the cardiovascular system by reducing blood pressure, improving endothelial function and preventing platelet aggregation. These properties make it a potential treatment for hypertension, atherosclerosis, and other cardiovascular diseases.

  4. Cancer Prevention: Lycopene has been found to possess anticancer activity by inhibiting cell proliferation and inducing apoptosis in various cancer cells. It has been studied for its potential use in treating cancers of the prostate, lung, breast, and colon.

  5. Prostate Health: Lycopene has been shown to have beneficial effects on the prostate gland. Studies suggest that lycopene may help to reduce the risk of developing prostate cancer and improve symptoms associated with benign prostatic hyperplasia (BPH).

Potential Effects: Lycopene may also have potential therapeutic effects in other conditions such as skin health, bone health, and eye health. There is ongoing research investigating the potential benefits of lycopene in these conditions.

Product Mechanism: The therapeutic effects of lycopene are thought to be mediated through several mechanisms. It activates the Nrf2 pathway which regulates antioxidant and cytoprotective gene expression. It also modulates various signaling pathways involved in inflammation, oxidative stress, and apoptosis. Lycopene inhibits the activation of NF-κB, a transcription factor that plays a key role in regulating the expression of genes involved in inflammation and immune responses.

Safety and Side Effects: Lycopene is generally considered safe when used as directed. However, high doses or prolonged use may cause gastrointestinal upset, headache, and dizziness. Lycopene may also interact with certain medications such as blood thinners and cholesterol-lowering drugs.

Dosing Information: There is no standard dosing for lycopene because it depends on the condition being treated. However, typical doses range from 8 to 30 mg per day, taken orally.

In Conclusion: Lycopene is a natural compound with promising therapeutic potential. Its antioxidant, anti-inflammatory, cardiovascular, and anticancer properties make it a valuable candidate for the development of new drugs. However, more research is needed to determine its efficacy, safety, and optimal dosing in humans. As with any dietary supplement, it is important to consult a healthcare professional before taking lycopene

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code